טוען...
Heart failure drug changes the mechanoenzymology of the cardiac myosin powerstroke
Omecamtiv mecarbil (OM), a putative heart failure therapeutic, increases cardiac contractility. We hypothesize that it does this by changing the structural kinetics of the myosin powerstroke. We tested this directly by performing transient time-resolved FRET on a ventricular cardiac myosin biosensor...
שמור ב:
| הוצא לאור ב: | Proc Natl Acad Sci U S A |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
National Academy of Sciences
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5347578/ https://ncbi.nlm.nih.gov/pubmed/28223517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1611698114 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|